112 related articles for article (PubMed ID: 21346352)
21. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.
Tripodi MF; Durante-Mangoni E; Fortunato R; Utili R; Zarrilli R
Int J Antimicrob Agents; 2007 Dec; 30(6):537-40. PubMed ID: 17851050
[TBL] [Abstract][Full Text] [Related]
22. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
Ruzin A; Keeney D; Bradford PA
J Antimicrob Chemother; 2007 May; 59(5):1001-4. PubMed ID: 17363424
[TBL] [Abstract][Full Text] [Related]
23. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide.
Pannek S; Higgins PG; Steinke P; Jonas D; Akova M; Bohnert JA; Seifert H; Kern WV
J Antimicrob Chemother; 2006 May; 57(5):970-4. PubMed ID: 16531429
[TBL] [Abstract][Full Text] [Related]
24. Clusters of imipenem-resistant Acinetobacter baumannii clones producing different carbapenemases in an intensive care unit.
Tsakris A; Ikonomidis A; Poulou A; Spanakis N; Vrizas D; Diomidous M; Pournaras S; Markou F
Clin Microbiol Infect; 2008 Jun; 14(6):588-94. PubMed ID: 18397334
[TBL] [Abstract][Full Text] [Related]
25. Cost-analysis of an intensive care unit closure due to an imipenem-resistant oxa-23 Acinetobacter baumannii outbreak.
Garlantézec R; Bourigault C; Boles JM; Prat G; Baron R; Tonnelier JM; Cosse M; Lefevre M; Jourdain S; Lelay G; Daniel L; Virmaux M; Le Du I; Tande D; Renault A; Lejeune B
J Hosp Infect; 2011 Feb; 77(2):174-5. PubMed ID: 21194794
[No Abstract] [Full Text] [Related]
26. Widespread occurrence of aminoglycoside resistance due to ArmA methylase in imipenem-resistant Acinetobacter baumannii isolates in China.
Yu YS; Zhou H; Yang Q; Chen YG; Li LJ
J Antimicrob Chemother; 2007 Aug; 60(2):454-5. PubMed ID: 17561497
[No Abstract] [Full Text] [Related]
27. IMP-4 and OXA beta-lactamases in Acinetobacter baumannii from Singapore.
Koh TH; Sng LH; Wang GC; Hsu LY; Zhao Y
J Antimicrob Chemother; 2007 Apr; 59(4):627-32. PubMed ID: 17284537
[TBL] [Abstract][Full Text] [Related]
28. Role of OXA-23 and AdeABC efflux pump for acquiring carbapenem resistance in an Acinetobacter baumannii strain carrying the blaOXA-66 gene.
Lee Y; Yum JH; Kim CK; Yong D; Jeon EH; Jeong SH; Ahn JY; Lee K
Ann Clin Lab Sci; 2010; 40(1):43-8. PubMed ID: 20124329
[TBL] [Abstract][Full Text] [Related]
29. [Mechanism of carbapenems resistance in Acinetobacter baumannii].
Wang H; Liu YM; Chen MJ; Sun HL; Xie XL; Xu YC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):567-72. PubMed ID: 14650160
[TBL] [Abstract][Full Text] [Related]
30. Distribution of the multidrug efflux pump genes, adeABC, adeDE and adeIJK, and class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
Lin L; Ling BD; Li XZ
Int J Antimicrob Agents; 2009 Jan; 33(1):27-32. PubMed ID: 18790612
[TBL] [Abstract][Full Text] [Related]
31. Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II.
Nemec A; Krízová L; Maixnerová M; Diancourt L; van der Reijden TJ; Brisse S; van den Broek P; Dijkshoorn L
J Antimicrob Chemother; 2008 Sep; 62(3):484-9. PubMed ID: 18477708
[TBL] [Abstract][Full Text] [Related]
32. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology.
Poirel L; Nordmann P
Clin Microbiol Infect; 2006 Sep; 12(9):826-36. PubMed ID: 16882287
[TBL] [Abstract][Full Text] [Related]
33. Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection.
Jamulitrat S; Arunpan P; Phainuphong P
J Med Assoc Thai; 2009 Mar; 92(3):413-9. PubMed ID: 19301737
[TBL] [Abstract][Full Text] [Related]
34. High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically related and unrelated Acinetobacter baumannii clinical isolates in Spain.
Ruiz M; Marti S; Fernandez-Cuenca F; Pascual A; Vila J
Clin Microbiol Infect; 2007 Dec; 13(12):1192-8. PubMed ID: 17850347
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and diversity of carbapenemases among imipenem-nonsusceptible Acinetobacter isolates in Korea: emergence of a novel OXA-182.
Kim CK; Lee Y; Lee H; Woo GJ; Song W; Kim MN; Lee WG; Jeong SH; Lee K; Chong Y
Diagn Microbiol Infect Dis; 2010 Dec; 68(4):432-8. PubMed ID: 20884158
[TBL] [Abstract][Full Text] [Related]
36. Carbapenemase and efflux pump genes in Acinetobacter calcoaceticus Acinetobacter baumannii complex strains from Singapore.
Koh TH; Sng LH; Wang GC; Hsu LY; Zhao Y
J Antimicrob Chemother; 2007 Nov; 60(5):1173-4. PubMed ID: 17768175
[No Abstract] [Full Text] [Related]
37. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
Song JY; Cheong HJ; Lee J; Sung AK; Kim WJ
Int J Antimicrob Agents; 2009 Jan; 33(1):33-9. PubMed ID: 18835761
[TBL] [Abstract][Full Text] [Related]
38. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City.
Quale J; Bratu S; Landman D; Heddurshetti R
Clin Infect Dis; 2003 Jul; 37(2):214-20. PubMed ID: 12856214
[TBL] [Abstract][Full Text] [Related]
39. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
Saballs M; Pujol M; Tubau F; Peña C; Montero A; Domínguez MA; Gudiol F; Ariza J
J Antimicrob Chemother; 2006 Sep; 58(3):697-700. PubMed ID: 16895941
[TBL] [Abstract][Full Text] [Related]
40. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.
Zavascki AP; Carvalhaes CG; Picão RC; Gales AC
Expert Rev Anti Infect Ther; 2010 Jan; 8(1):71-93. PubMed ID: 20014903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
